Skip to main content

Advertisement

SpringerLink
Log in

Management of Hepatic Encephalopathy Not Responsive to First-Line Treatments

  • Liver (J Bajaj, Section Editor)
  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Abstract

Purpose of review

Hepatic encephalopathy (HE) is a neuropsychiatric syndrome that occurs in up to 30% of patients with cirrhosis. HE may be a consequence of pure liver failure, as in patients with fulminant hepatitis, or of the combination of liver failure and portal-systemic shunting, as in patients with liver cirrhosis. Episodes of HE are usually related to precipitating events, such as infections or gastrointestinal bleeding; a minority of cirrhotic patients experienced a chronic HE, refractory to standard medical treatment. The prevention of HE recurrence, after the first episode of HE, could be obtained by the administration of prophylactic therapy with lactulose, rifaximin or a combination of both.

The aim of this review is to clarify some key points in the management of cirrhotic patients with HE, not responsive to first line treatment.

Recent findings

Recent studies investigated the role of fecal microbiota transplantation in the treatment of HE with promising results, but further investigations are needed.

Summary

In a cirrhotic patient with acute cognitive impairment, the correct diagnosis of HE, after excluding other causes of neurological diseases, is mandatory for the correct management of the precipitating factors and for the treatment. In patients not responsive to standard treatment, the probable precipitating factors have not been correctly identified, multiple precipitating events are coexisting or a new precipitating event is superimposed.

In some patients with recurrent HE, characterized by persistent alterations in neurological symptoms, without specific precipitants events, the presence of spontaneous or iatrogenic shunts should be investigated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

HE:

hepatic encephalopathy

TIPS:

transjugular intrahepatic porto-systemic shunt

SPSS:

spontaneous portal-systemic shunt

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Amodio P, Bemeur C, Butterworth R, Cordoba J, Kato A, Montagnese S, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology. 2013;58:325–36.

    Article  CAS  PubMed  Google Scholar 

  2. •• Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715–35. These International practice guidelines could be very useful for practitioners in the management of patients with HE

    Article  PubMed  Google Scholar 

  3. • Riggio O, Nardelli S, Gioia S, Lucidi C, Merli M. Management of hepatic encephalopathy as an inpatient. Clinical Liver Disease. 2015;5(3):79–82. This paper could be useful to guide physicians in differential diagnosis of HE

    Article  Google Scholar 

  4. Pantham G, Mullen KD. Practical issues in the management of overt hepatic encephalopathy. Gastroenterol Hepatol (N Y). 2017;13(11):659–65.

    PubMed Central  Google Scholar 

  5. Simón-Talero M, García-Martínez R, Torrens M, et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol. 2013;59:1184–92.

    Article  PubMed  Google Scholar 

  6. Sharma BC, Singh J, Srivastava S, et al. Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy. J Gastroenterol Hepatol. 2017;32:1234–9.

    Article  CAS  PubMed  Google Scholar 

  7. Sharma BC, Sharma P, Lunia MK, et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108:1458–63.

    Article  CAS  PubMed  Google Scholar 

  8. Rahimi RS, Singal AG, Cuthbert JA, et al. Lactulose vs polyethylene glycol 3350-electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern Med. 2014;174:1727–33.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Sidhu SS, Sharma BC, Goyal O, et al. L-ornithine L-aspartate in bouts of overt hepatic encephalopathy. Hepatology. 2017. Jul 27; https://doi.org/10.1002/hep.29410.

  10. •• Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology. 2017;66:1727–38. This study is very interesting because it demonstrated for the first time the efficacy of fecal microbiota transplant in the treatment of HE

    Article  CAS  PubMed  Google Scholar 

  11. Schmidt L, Gørtz S, Wohlfahrt J, Melbye M, Munch TN. Recurrence of subdural haematoma in a population-based cohort—risks and predictive factors. PLoS One. 2015;10(10):e0140450.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Donovan LM, Kress WL, Strnad LC, et al. Low likelihood of intracranial hemorrhage in patients with cirrhosis and altered mental status. Clin Gastroenterol Hepatol. 2015;13(1):165–9.

    Article  PubMed  Google Scholar 

  13. Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology. 2009;137(3):885–91. 891

  14. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–81.

    Article  CAS  PubMed  Google Scholar 

  15. • Riggio O, Efrati C, Catalano C, Pediconi F, Mecarelli O, Accornero N, et al. High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology. 2005;42(5):1158–65. This study demonstrated that in patients with recurrent HE, there is a high prevalence of large porto systemic shunts that need to be searched by a CT scan

    Article  PubMed  Google Scholar 

  16. Ohnishi K, Sato S, Saito M, Terabayashi H, Nakayama T, Saito M, et al. Clinical and hemodynamic features in cirrhotic patients having a large spontaneous splenorenal and/or gastrorenal shunt. Am J Gastroenterol. 1986;81:450–5.

    CAS  PubMed  Google Scholar 

  17. Simón-Talero M, Roccarina D, Martínez J, Lampichler K, Baiges A, Low G, et al. Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis. Gastroenterology. 2018 Jan 20. pii: S0016-5085(18)30069-6.

  18. Rössle M. TIPS: 25 years later. J Hepatol. 2013;59(5):1081–93. https://doi.org/10.1016/j.jhep.2013.06.014. Review

    Article  PubMed  Google Scholar 

  19. Bureau C, Garcia-Pagan JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology. 2004;126:469–75.

    Article  PubMed  Google Scholar 

  20. Riggio O, Nardelli S, Moscucci F, Pasquale C, Ridola L, Merli M. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Clin Liver Dis. 2012 Feb;16(1):133–46.

    Article  PubMed  Google Scholar 

  21. Kochar N, Tripathi D, Ireland H, et al. Transjugular intrahepatic portosystemic stent shunt (TIPSS) modification in the management of post-TIPSS refractory hepatic encephalopathy. Gut. 2006;55:617–23.

    Article  Google Scholar 

  22. Riggio O, Angeloni S, Salvatori FM, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008;103:2738–46.

    Article  PubMed  Google Scholar 

  23. Laleman W, Simon-Talero M, Maleux G, Perez M, Ameloot K, Soriano G, et al. EASL-CLIF-Consortium. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology. 2013;57(6):2448–57.

    Article  PubMed  Google Scholar 

  24. An J, Kim KW, Han S, et al. Improvment in survival associated with embolisation of spontaneous portosystemic shunt in patients with recurrent hepatic encephalopathy. Aliment Pharmacol Ther. 2014;39(12):1418–26.

    Article  CAS  PubMed  Google Scholar 

  25. Gwon D, Kim Y, Ko G, Kim J, Ko H, Kim J, et al. Vascular plug-assisted retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy: a prospective multicenter study. J Vasc Interv Radiol. 2015;26:1589–95.

    Article  PubMed  Google Scholar 

  26. Mukund A, Deogaonkar G, Rajesh S, et al. Safety and Efficacy of Sodium Tetradecyl Sulfate and Lipiodol Foam in Balloon-OccludedRetrograde Transvenous Obliteration (BRTO) for Large Porto-Systemic Shunts. Cardiovasc Intervent Radiol. 2017;40(7):1010–6.

    Article  PubMed  Google Scholar 

  27. Bureau C, Thabut D, Oberti F, et al. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites. Gastroenterology. 2017 Jan;152(1):157–63.

    Article  PubMed  Google Scholar 

  28. De Santis A, Nardelli S, Bassanelli C, et al. The modification of splenic stiffness on acoustic radiation force impulse parallels the variation of portal pressure induced by transjugular intrahepatic portosystemic shunt. J Gastroenterol Hepatol. 2017.

  29. Nardelli S, Gioia S, Pasquale C, et al. Cognitive impairment predicts the occurrence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Am J Gastroenterol. 2016;111(4):523–8.

    Article  PubMed  Google Scholar 

  30. Cookson DT, Zaman Z, Gordon-Smith J, et al. Management of transjugular intrahepatic portosystemic shunt (TIPS)-associated refractory hepatic encephalopathy by shunt reduction using the parallel technique: outcomes of a retrospective case series. Cardiovasc Intervent Radiol. 2011;34:92–9.

    Article  PubMed  Google Scholar 

  31. Fanelli F, Salvatori FM, Rabuffi P, et al. Management of refractory hepatic encephalopathy after insertion of TIPS: long-term results of shunt reduction with hourglass-shaped balloon-expandable stent-graft. Am J Roentgenol. 2009;193:1696–702.

    Article  Google Scholar 

  32. Bajaj JS, Schubert CM, Heuman DM, Wade JB, Gibson DP, Topaz A, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology. 2010;138(7):2332–40. https://doi.org/10.1053/j.gastro.2010.02.015.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy

    Silvia Nardelli MD, Stefania Gioia MD & Oliviero Riggio Prof, MD, PhD

  2. Department of Gastroenterology, Santa Maria Goretti Hospital, Sapienza Polo Pontino, Latina, Italy

    Lorenzo Ridola MD, PhD

Authors
  1. Silvia Nardelli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lorenzo Ridola MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefania Gioia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Oliviero Riggio Prof, MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silvia Nardelli MD.

Ethics declarations

Conflict of Interest

Silvia Nardelli, Lorenzo Ridola, Stefanie Gioia, and Oliviero Riggio declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Liver

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nardelli, S., Ridola, L., Gioia, S. et al. Management of Hepatic Encephalopathy Not Responsive to First-Line Treatments. Curr Treat Options Gastro 16, 253–259 (2018). https://doi.org/10.1007/s11938-018-0183-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-018-0183-1

Keywords

Search

Navigation